Draupnir raises size of PolyPeptide block due to high demand
The majority shareholders of the Swiss pharma chemicals firm sold Sfr171 of shares at the end of the post-IPO lockup
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: